Floatz logo

MOXIFLOXACIN

Bronchiectasis, Non-Cystic Fibrosis

Assiut UniversitySmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

21 Active assets in the Bronchiectasis, Non-Cystic Fibrosis cohort.

Asset / SponsorPhaseRating
Ciprofloxacin
Centre Hospitalier Intercommunal Creteil
Phase 4BBB
Azithromycin
Assiut University
Phase 4BBB
Lipitor
University of Edinburgh
Phase 4BB
Theophylline
The First Affiliated Hospital of Guangzhou Medical University
Phase 4BB
Roflumilast
The University of Hong Kong
Phase 3BB

View all 50 →

Same molecule, other indications

MOXIFLOXACIN is also rated in:

bacterial infectious disease with sepsisDormant
BB
Indicative ·
64 / 100
View asset →
Hodgkins lymphomaDormant
B
Indicative ·
62 / 100
View asset →
plasma cell myelomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →